Balestri Riccardo, Rech Giulia, Tasin Laura, Rizzoli Laura, Girardelli Carlo Renè
a Division of Dermatology , S. Chiara Hospital , Trento , Italy.
J Dermatolog Treat. 2018;29(sup1):3-5. doi: 10.1080/09546634.2018.1527993.
Acrodermatitis continua of Hallopeau is considered an uncommon variant of pustular psoriasis, characterized by a relapsing, sterile, pustular eruption of hands and feet. It is not easily treated by antipsoriatic therapies, and may progress toward sclerosis and osteolysis. Numerous topical and systemic treatments have been used, with inconsistent results. The therapeutic response of pustular psoriasis to biologics supports the pivotal role of the tumor necrosis factor (TNF)-α/interleukin (IL)-23/IL-17/IL-22 axis in the pathogenesis of the disorder. Based on these data, secukinumab was used in a patient with uncontrolled acrodermatitis continua of Hallopeau. We described a case of secukinumab treated patient with uncontrolled acrodermatitis continua of Hallopeau. Our experience suggests that secukinumab may represent a suitable choice for the management of acrodermatitis continua of Hallopeau resistant to other treatments.
哈洛佩au连续性肢端皮炎被认为是脓疱型银屑病的一种罕见变体，其特征为手足反复出现无菌性脓疱疹。抗银屑病疗法对其治疗效果不佳，且可能进展为硬化和骨质溶解。已使用了多种局部和全身治疗方法，但结果不一。脓疱型银屑病对生物制剂的治疗反应支持肿瘤坏死因子（TNF）-α/白细胞介素（IL）-23/IL-17/IL-22轴在该疾病发病机制中的关键作用。基于这些数据，司库奇尤单抗被用于一名哈洛佩au连续性肢端皮炎控制不佳的患者。我们描述了一例接受司库奇尤单抗治疗的哈洛佩au连续性肢端皮炎控制不佳的患者。我们的经验表明，司库奇尤单抗可能是治疗对其他治疗耐药的哈洛佩au连续性肢端皮炎的合适选择。
